These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 29249444)
1. Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. Proietti M; Lip GYH Int J Cardiol; 2018 Feb; 252():96-100. PubMed ID: 29249444 [TBL] [Abstract][Full Text] [Related]
2. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888 [TBL] [Abstract][Full Text] [Related]
3. Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. Proietti M; Lane DA; Lip GYH EBioMedicine; 2016 Jun; 8():309-316. PubMed ID: 27428440 [TBL] [Abstract][Full Text] [Related]
4. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Steinberg BA; Kim S; Piccini JP; Fonarow GC; Lopes RD; Thomas L; Ezekowitz MD; Ansell J; Kowey P; Singer DE; Gersh B; Mahaffey KW; Hylek E; Go AS; Chang P; Peterson ED; Circulation; 2013 Aug; 128(7):721-8. PubMed ID: 23861512 [TBL] [Abstract][Full Text] [Related]
5. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184 [TBL] [Abstract][Full Text] [Related]
6. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Ho CW; Ho MH; Chan PH; Hai JJ; Cheung E; Yeung CY; Lau KK; Chan KH; Lau CP; Lip GY; Leung GK; Tse HF; Siu CW Stroke; 2015 Jan; 46(1):23-30. PubMed ID: 25406148 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry. Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825 [TBL] [Abstract][Full Text] [Related]
8. Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin. Senoo K; Lip GY Stroke; 2016 Jun; 47(6):1665-8. PubMed ID: 27125527 [TBL] [Abstract][Full Text] [Related]
9. Geographical differences in thromboembolic and bleeding risks in patients with non-valvular atrial fibrillation: An ancillary analysis from the SPORTIF trials. Proietti M; Lip GY Int J Cardiol; 2017 Jun; 236():244-248. PubMed ID: 28284508 [TBL] [Abstract][Full Text] [Related]
10. Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. Proietti M; Airaksinen KEJ; Rubboli A; Schlitt A; Kiviniemi T; Karjalainen PP; Lip GYH; Clin Res Cardiol; 2017 Jun; 106(6):420-427. PubMed ID: 28078448 [TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL; Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB; Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971 [TBL] [Abstract][Full Text] [Related]
13. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. Lip GY; Frison L; Halperin JL; Lane DA J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555 [TBL] [Abstract][Full Text] [Related]
14. Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. Proietti M; Lip GY Am J Med; 2016 Oct; 129(10):1110-6. PubMed ID: 27086494 [TBL] [Abstract][Full Text] [Related]
15. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Lehto M; Niiranen J; Korhonen P; Mehtälä J; Khanfir H; Hoti F; Lassila R; Raatikainen P Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):657-665. PubMed ID: 28317274 [TBL] [Abstract][Full Text] [Related]
16. Prevention of stroke in patients with atrial fibrillation. Olsson SB; Halperin JL Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916 [TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448 [TBL] [Abstract][Full Text] [Related]
18. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK; PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741 [TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. White HD; Gruber M; Feyzi J; Kaatz S; Tse HF; Husted S; Albers GW Arch Intern Med; 2007 Feb; 167(3):239-45. PubMed ID: 17296878 [TBL] [Abstract][Full Text] [Related]
20. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]